Transthera Sciences (Nanjing), Inc.
π¨π³China
- Country
- π¨π³China
- Ownership
- Holding
- Established
- 2014-04-15
- Employees
- 51
- Market Cap
- -
- Website
- http://www.transtherabio.com
Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04830501
- Locations
- π¨π³
Tri-Service General Hospital, Taipei, Taiwan
π¨π³Taipei Medical University Hospital, Taipei, Taiwan
π¨π³National Cheng Kung University Hospital, Tainan, Taiwan
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 203
- Registration Number
- NCT04742959
- Locations
- πΊπΈ
UT Southwestern Medical Center, Dallas, Texas, United States
πΊπΈCity of Hope, Duarte, California, United States
πΊπΈGabrail Cancer Center Research, Canton, Ohio, United States
Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy Volunteers
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04705922
- Locations
- πΊπΈ
Pharmaron CPC, Baltimore, Maryland, United States
Phase I, First-In-Human Study of TT-00920 in Healthy Subjects
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04364789
- Locations
- πΊπΈ
Early Phase Clinical Unit Glendale Adventist Medical Center, Los Angeles, California, United States
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03654547
- Locations
- π¨π³
Cancer Hopital Chinese Academy of Medical Sciences, Beijing, Beijing, China
πΊπΈMD Anderson Cancer Center, Houston, Texas, United States
Β© Copyright 2024. All Rights Reserved by MedPath